Generated by AI
Rani Therapeutics Holdings, Inc. Class A Common Stock represents equity in Rani Therapeutics, a clinical-stage biotherapeutics company focused on oral delivery technologies for biologics and other drugs. The company’s core product is the RaniPill capsule, a proprietary platform designed to administer large-molecule therapies through the gastrointestinal tract, offering an alternative to injections and infusions. Rani Therapeutics develops this technology for use across multiple therapeutic areas, including peptides, proteins, antibodies, and oligonucleotides. Its business is centered on advancing drug-delivery solutions that may support patients, physicians, and healthcare systems by making biologic administration more convenient. The company operates in the biotechnology and health care life sciences sectors, where oral delivery platforms are an important area of innovation.
Website2051 Ringwood Avenue
San Jose, CA, 95131
United States
The latest articles about RANI.
Summary of Aug 19's posts. Generated by AI.
Summary of Jul 22's posts. Generated by AI.
No summary yet.
Summary of Jul 22's posts. Generated by AI.
Investors talking about RANI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.